Research programme: alpha-1-microglobulin - A1M Pharma

Drug Profile

Research programme: alpha-1-microglobulin - A1M Pharma

Alternative Names: A1M-001; Alpha-1-microglobulin - A1M Pharma; α1-microglobulin - A1M Pharma

Latest Information Update: 10 Jul 2014

Price : $50

At a glance

  • Originator A1M Pharma AB
  • Class Recombinant proteins
  • Mechanism of Action Free radical scavengers; Haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Preeclampsia

Most Recent Events

  • 08 Jul 2014 A1M 001 receives Orphan Drug status for Preeclampsia in European Union
  • 08 Jul 2014 Preclinical trials in Preeclampsia in Sweden (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top